Skip to content

Clinical study on residual cardiovascular risk and long-term benefit of IPE in patients with ACS

Clinical study on residual cardiovascular risk and long-term benefit of IPE in patients with ACS

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400081397
Enrollment
Unknown
Registered
2024-02-29
Start date
2023-07-05
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome

Interventions

experimental group:taking IPE and statins
control group:Taking statins and lifestyle interventions

Sponsors

The Seconed Affiliated Hospital of Xi'an Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Age =40 years old 2. ACS patients, including STEMI, NSTEMI and UA, with coronary artery stenosis confirmed by CAG for revascularization, and at least one of the following: ? abnormal elevation of myocardial injury markers; ECG changes consistent with ischemia or infarction 3. Moderate-intensity oral statin therapy for more than 4 weeks 4. Triglyceride TG > 2.3mmol/L 5. Low density lipoprotein cholesterol LDL-c<2.6 mmol/L

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women 2. Patients with previous seafood allergy 3. Patients with severe liver and kidney dysfunction 4. Use of other classes of lipid-lowering drugs (including PCSK9i, fibrates, etc.)

Design outcomes

Primary

MeasureTime frame
triglyceride;low density lipoprotein;non-HDL cholesterol;Lipoprotein a;

Secondary

MeasureTime frame
Ultrasound measurements of cervical vessels;Atherogenic index of plasma;

Countries

China

Contacts

Public ContactHuijuan Kou

The second affiliated hospital of Xi'an Jiaotong University

khjsarah@163.com+86 136 3028 7640

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026